In this episode, John Gagliano and Sheff Sheffield discuss the current state of the biotech market as they approach the end of the year. They reflect on recent trading successes and challenges, emphasizing the importance of understanding catalysts and market reactions. The conversation also highlights the significance of insider trading and institutional movements in stock performance. Finally, they explore upcoming catalysts and provide insights into their stock watchlist for the remainder o...
All content for Biotech Bulls & Breakthroughs is the property of BioPharmCatalyst and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, John Gagliano and Sheff Sheffield discuss the current state of the biotech market as they approach the end of the year. They reflect on recent trading successes and challenges, emphasizing the importance of understanding catalysts and market reactions. The conversation also highlights the significance of insider trading and institutional movements in stock performance. Finally, they explore upcoming catalysts and provide insights into their stock watchlist for the remainder o...
Biopharma Industry: Insights from BioSpace Senior Editor Annalee Armstrong
Biotech Bulls & Breakthroughs
30 minutes
3 months ago
Biopharma Industry: Insights from BioSpace Senior Editor Annalee Armstrong
In this episode of Biotech Bulls and Breakthroughs, host John Gagliano speaks with Annalee Armstrong, Senior Editor at BioSpace, about the current state of the biopharma industry. They discuss exciting developments in neurodegenerative diseases, the hype surrounding GLP-1 drugs, the future of oncology, the psychedelic drug market, the role of the FDA, and the impact of AI on drug discovery. Annalee emphasizes the need for certainty in the biotech industry and the importance of focusing on goo...
Biotech Bulls & Breakthroughs
In this episode, John Gagliano and Sheff Sheffield discuss the current state of the biotech market as they approach the end of the year. They reflect on recent trading successes and challenges, emphasizing the importance of understanding catalysts and market reactions. The conversation also highlights the significance of insider trading and institutional movements in stock performance. Finally, they explore upcoming catalysts and provide insights into their stock watchlist for the remainder o...
